ACC 2022 | APOLLO

Lipoprotein a (Lp a) is an important risk factor for atherothrombosis and atherosclerotic cardiovascular disease, but it has no approved treatments to this day.  

ACC 2022 | Estudio APOLLO

The aim of this randomized study in phase 1 was to assess adverse events and siRNA tolerance (small interfering RNA) to reduce liver production of Lp a and assess plasma concentration with different doses. 

It included 32 patients with Lp a serum values ≥ 150 nmol/l and no CAD. Mean age was 50 and 53% were women. Participants were randomized to receiving placebo and subcutaneous doses of 30 mg, 60 mg, 100 mg, 300 mg, and 600 mg of SLN360.

Primary end point was safety and tolerance. Secondary end point was changes in plasma concentration of Lp a at 150-day followup. 

There were no serious adverse events (the most frequent were headache, sore injection site and transient elevation of liver enzymes). As regards the secondary end point, Lp a saw a 70 and 80% reduction after the administration of 300 and 600 mg of SLN360 respectively. This was observed at followup up to 150 days. 

Read also: ACC 2022 – Estudio Complete Trial QoL: Revascularización completa en el SCACEST.

Finally, there was a 20-30% reduction of LDL and apoB as well.

Conclusion

In this phase 1 study with 32 participants with elevated Lp a and no CAD, siRNA SLN360 was well tolerated, and there was a reduction of plasma concentration of Lp a depending of the dose. We need further study to better assess safety and efficacy. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board, SOLACI.org .

Reference: Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...